Alexander J Millman, Boatemaa Ntiri-Reid, Risha Irvin, Maggie H Kaufmann, Andrew Aronsohn, Jeffrey S Duchin, John D Scott, Claudia Vellozzi
{"title":"慢性丙型肝炎病毒感染获得治疗的障碍:一个病例系列。","authors":"Alexander J Millman, Boatemaa Ntiri-Reid, Risha Irvin, Maggie H Kaufmann, Andrew Aronsohn, Jeffrey S Duchin, John D Scott, Claudia Vellozzi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Restrictive policies on access to new, curative hepatitis C treatments represent a substantial barrier to treating patients infected with hepatitis C. This case series demonstrates challenges experienced by patients and practitioners in accessing these treatments and highlights several strategies for navigating the treatment preauthorization process.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678961/pdf/tam-25-110.pdf","citationCount":"0","resultStr":"{\"title\":\"Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.\",\"authors\":\"Alexander J Millman, Boatemaa Ntiri-Reid, Risha Irvin, Maggie H Kaufmann, Andrew Aronsohn, Jeffrey S Duchin, John D Scott, Claudia Vellozzi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Restrictive policies on access to new, curative hepatitis C treatments represent a substantial barrier to treating patients infected with hepatitis C. This case series demonstrates challenges experienced by patients and practitioners in accessing these treatments and highlights several strategies for navigating the treatment preauthorization process.</p>\",\"PeriodicalId\":38738,\"journal\":{\"name\":\"Topics in antiviral medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678961/pdf/tam-25-110.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Topics in antiviral medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in antiviral medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.
Restrictive policies on access to new, curative hepatitis C treatments represent a substantial barrier to treating patients infected with hepatitis C. This case series demonstrates challenges experienced by patients and practitioners in accessing these treatments and highlights several strategies for navigating the treatment preauthorization process.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
